Published on in Vol 6, No 1 (2014):

Surveillance of Human Papilloma Virus in the United States to Evaluate Vaccine Impact

Surveillance of Human Papilloma Virus in the United States to Evaluate Vaccine Impact

Surveillance of Human Papilloma Virus in the United States to Evaluate Vaccine Impact

Authors of this article:

Andrew Wilson1 ;   Ryan Welch2 ;   Rosemary She3
The full text of this article is available as a PDF download by clicking here.

Background: Human papillomavirus (HPV) is a vaccine-preventable virus that can cause cervical cancer. Widespread positivity rates in target groups before and since the introduction of the vaccine in 2006 would provide insight into the uptake of the vaccine. Data: Archived patient records were queried and formatted to allow analysis and determination of positivity rates. Results/Conclusions: Positivity rate estimates show a decrease in positivity for younger age groups. From 2004 to 2013, high-risk rates dropped 20% in women 14-24 years. After the vaccine introduction, HPV positivity has declined at a rate consistent with widespread inoculation, especially in younger women.